Literature DB >> 19141376

Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis?

Jude M Abadie1, K H van Hoeven, Justin M Wells.   

Abstract

Renal impairment and polyclonal hypergammaglobulinemia may abnormally increase the serum free light chain (sFLC) ratio, giving false-positive results with current reference intervals. We measured sFLCs with concomitant serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP) in 281 patients. Results were interpreted relative to renal function (serum creatinine concentrations) and polyclonal hypergammaglobulinemia. Overall, 78 plasma cell disorders (PCDs) were detected with the serum panel of SPEP/sFLC vs 76 with SPEP/UPEP. In 13 samples with negative SPEP/UPEP, mildly increased ratios up to 3.1 (normal, 0.26-1.65) were observed: 10 were associated with increased serum creatinine and 1 with polyclonal hypergammaglobulinemia; 2 were unassociated with either condition. In 2 samples, decreased kappa/lambda ratios were identified that were clinically significant despite normal SPEP/UPEP. Two monoclonal gammopathies were identified with UPEP and sFLC, but samples were normal with SPEP. Screening for PCDs with a serum panel consisting of SPEP and the sFLC assays is a highly sensitive approach that could eliminate the need for UPEP. A mildly increased kappa/lambda ratio up to 3.1 was observed with increased serum creatinine and/or polyclonal hypergammaglobulinemia that was consistent with pathophysiologic changes, and, therefore, renal reference intervals are recommended.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141376     DOI: 10.1309/AJCPR2M4EUYNHLGM

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).

Authors:  Pooja Phull; Vaishali Sanchorawala; Lawreen H Connors; Gheorghe Doros; Frederick L Ruberg; John L Berk; Shayna Sarosiek
Journal:  Amyloid       Date:  2018-02-09       Impact factor: 7.141

Review 2.  Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.

Authors:  A J Greenberg; C M Vachon; S V Rajkumar
Journal:  Leukemia       Date:  2011-12-23       Impact factor: 11.528

3.  Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome.

Authors:  Trista Stankowski-Drengler; Morie A Gertz; Jerry A Katzmann; Martha Q Lacy; Shaji Kumar; Nelson Leung; Suzanne R Hayman; Francis Buadi; Robert A Kyle; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2010-06       Impact factor: 10.047

4.  Comment on "Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy".

Authors:  Antony R Parker; Oscar Berlanga; Stephen Harding
Journal:  Biomed Res Int       Date:  2015-03-12       Impact factor: 3.411

5.  Using Two Detection Methods to Observe the Changes and Significance of Free Light Chain in Serum and Urine in Patients with Renal Insufficiency.

Authors:  Lengnan Xu; Ban Zhao; Ying Sun; Songlan Wang; Xianguang Chen; Yonghui Mao
Journal:  Biomed Res Int       Date:  2022-03-29       Impact factor: 3.411

Review 6.  Clinical Clues and Diagnostic Workup of Cardiac Amyloidosis.

Authors:  Sajan S Gill; Eric Fellin; Lisa Stampke; Yunazi Zhao; Ahmad Masri
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14

7.  Cetuximab-Associated Crescentic Diffuse Proliferative Glomerulonephritis.

Authors:  Sukesh Manthri; Sindhura Bandaru; Anthony Chang; Tamer Hudali
Journal:  Case Rep Nephrol       Date:  2017-11-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.